Relay and iTeos join IPO deluge while Akouos and Fusion decide they can earn more
They just don’t. Stop. Coming.
If biotechs have learned anything during the pandemic economy, it’s that investors have become eager to jump in to buy stock in drugmakers. And a week after we saw two early-stage US biotechs and a large South Korean biopharma fetch more than $1.2 billion — and two weeks after we saw three biotechs raise $200 million-plus before they entered the clinic — two more drugmakers have decided to go public and two others decided they could raise millions more than they had originally asked.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.